Heart FailureWeRoaM:NCT06969560
WeRoaM: Wearable Remote Monitoring in Heart Failure
An observational study of Heart Failure, run by University of Alberta at 4 sites in Canada.
Trial summary
Remote physiologic monitoring (RPM) of heart failure (HF) patients with a virtual platform is well established in adult care. However, this technology remains untested in pediatrics and care continues to rely on a hospital-based model which presents challenges in providing equitable access to care for those with lower… Read more about this study
- Who is it for?
- Ages 8 to 18 years
- Conditions the study is for
- Heart Failure
- What is being tested?
- Remote Physiologic Monitoring (RPM)
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 4 sitesCanada
- Study dates
- 24 Feb 2025to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: This study will enroll 100 paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy (with systolic or diastolic dysfunction), subjects with congenital heart disease with biventricular or univentricular physiology plus systemic ventricular dysfunction from 4 tertiary heart failure care centres.
Who may be able to join
- Patients from 8-18 years of age who are outpatients at time of study enrollment.
- Patients with a chest size of at least 69.85 cm in perimeter/circumference (as measured under the pectoral muscles)
- Patients at-risk for heart failure and with American Heart Association (AHA) Stage B-D Heart Failure will be included in this study irrespective of heart failure medication use.
- HF etiologies include: congenital cardiac malformation with systemic ventricular systolic dysfunction, idiopathic cardiomyopathy, familial/inherited and/or genetic cardiomyopathy, history of myocarditis with persistent ventricular dysfunction, neuromuscular disorder, inborn error of metabolism, mitochondrial disorder, acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional), ischemic (e.g., Kawasaki disease and post-operative HF), and left ventricular non-compaction, restrictive cardiomyopathy and HCM with systolic or diastolic dysfunction.
Who cannot join
- Patients within 3 months of a surgery.
- Patients supported by ventricular assist device at study onset.
- Inability to use technology due to physical or cognitive impairment in the patient or caregiver.
- Non-English speaking.
- Patients who have an implantable cardiac defibrillator or pacemaker
- Patients whose chest size is too large or small to fit available sizes of the Skiin device.
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada4 sites, 4 recruiting
- Recruiting
Stollery Children's Hospital
Edmonton, Alberta, T6G 2B7
Jennifer L Conway, MD, MSc, 780-407-4848, jennifer.conway2@ahs.ca
Tara L Pidborochynski, MSc, 780-407-1899, tara.pidborochynski@ahs.ca
- Not yet recruiting
CHU Sainte-Justine
Montreal, Quebec, QC H3T
Nassiba Alami Laroussi, MD, nassiba.alami.med@ssss.gouv.qc
Frederique Provencher, frederique.provencher.hsj@ssss.gouv.qc.ca
- Not yet recruiting
The Hospital for Sick Children
Toronto, Ontario, M5G 1E8
Aamir Jeewa, MD, 416-813-6140, aamir.jeewa@sickkids.ca
Diana Balmer-Minnes, diana.balmer-minnes@sickkids.ca
- Not yet recruiting
BC Children's Hospital
Vancouver, British Columbia, V6H 3N1
Kathryn Armstrong, MD, kathryn.armstrong@cw.bc.ca
Melanie Kardel, Melanie.Kardel@bcchr.ca
About this study
Official title: There's No Place Like Home…Feasibility of Remote Physiological Monitoring in Childhood Heart Failure
Remote physiologic monitoring (RPM) of heart failure (HF) patients with a virtual platform is well established in adult care. However, this technology remains untested in pediatrics and care continues to rely on a hospital-based model which presents challenges in providing equitable access to care for those with lower socio-economic status or living remotely. Telemonitoring technology tailored for children with machine-based algorithms to predict deterioration is needed to facilitate the equitable provision of safe, home-based care, especially in vulnerable populations.
This study will enroll 100 pediatric outpatients with or at risk of deteriorating HF from 4 tertiary pediatric heart failure care centres in Canada. We will use a wearable Bluetooth enabled textile (Skiin device), developed by Myant Inc (Toronto, ON), that can monitor heart rate, heart rhythm, respiratory rate and activity, together with additional home-based monitoring of blood pressure (BP), oxygen saturations and weight. The smart textile will be paired to an RPM platform, SphygmoTM (mmHG Inc).
The goal of this project is to assess the feasibility and acceptability of RPM in pediatrics and validate a RPM-based risk prediction model for pediatric HF patients.
Read the detailed description
Remote physiologic monitoring (RPM) refers to utilizing non-invasive medical devices to obtain physiologic data, such as pulse oximetry, blood pressure, weight, and electrocardiography at home. Recent advances in RPM have facilitated improved home-based care, reduced hospitalizations, and improved quality of life in adult heart failure populations. Additionally, the integration of multiple physiologic variables acquired through remote physiologic monitoring into machine learning algorithms has been shown to predict hospitalization for heart failure. Previous paediatric studies have demonstrated the utility of incorporating multiple physiologic variables into risk prediction algorithms for cardiac events. This is particularly important in heart failure cohorts where limits of acceptability are often nuanced and patient specific. The use of multiple physiologic parameters creates a more comprehensive insight into the complex pathophysiologic changes in heart failure.
However, the use of RPM devices in children remains limited due to a lack of validated devices and uncertainty about the acceptability and uptake of such interventions. This is partly due to challenges developing devices that can be easily applied, and digital platforms suited to the wider range and variability in body sizes and physiologic parameters. Thus, care of children with heart failure continues to rely on hospital-based models, where tertiary heart failure centers serve large geographically and socio-economically diverse populations. A validated paediatric virtual home monitoring system using RPM to predict clinical deterioration could safely facilitate earlier discharge, reduce the need for outpatient hospital visits, and potentially improve outcomes while minimizing family social disruption and school absence.
The overarching goal of this project is to assess the feasibility of RPM in paediatrics and validate a RPM based risk prediction model for paediatric patients with or at-risk of heart failure, with a view to facilitating safe home-based care across geographically and socially diverse urban, rural, and remote communities. To achieve this goal, this study proposes to utilize a wearable Bluetooth enabled textile (Skiin Device) that can monitor heart rate and rhythm, respiratory rate and activity, together with additional home-based monitoring of blood pressure, oxygen saturations and weight. The textile, developed by Myant (Toronto, ON) has completed pilot testing at SickKids to assess its validity in an outpatient setting (NCT04305340). The Skiin textile will be paired to its software solution, the Myant Health Platform (MHP), which comprises the Skiin Connected Life App (phone application), the Myant Back End (cloud storage of data) and the Myant Virtual Clinical Portal (internet browser visualization of data collected). The Skiin Connected Life App will be used for collection of ECG, heart rate, body temperature, and physical activity throughout the day, and can generate the following average metric for each night when the device is used: resting heart rate, respiratory rate, resting heart rate variability, sleep duration, body temperature.
The MHP will be paired with another RPM platform, SphygmoTM (mmHG Inc). The Sphygmo™ platform consists of a smartphone App (Android, iOS), which can be linked with Bluetooth-compatible devices for automated uploading of measurements to a clinician portal. This platform, originally developed for adults, has the ability to connect with blood pressure, heart rate, weight, and oxygen saturation devices. This platform will be used for collection of additional physiologic data as above and is currently under study at Stollery Children's Hospital. The two systems will have a single-sign on feature allowing their integrated use by the patient, their families, and the research team. We will leverage descriptive and predictive analytics to augment clinician monitoring by defining trajectories and longitudinally predicting risk of key adverse outcomes.
Study Objectives Primary Objectives
- To investigate the feasibility of a remote physiological monitor using a textile smart garment (Skiin devices) using the Skiin Connected Life App along with additional standard home monitoring tools (BP monitor, weigh scales) that are paired with a Bluetooth enabled app (SphygmoTM)
- To test the acceptability of a remote physiological monitor using a textile smart garment (Skiin devices) along with the acceptability of a Bluetooth enabled app (SphygmoTM)
Secondary Objectives
- To leverage analytical methods to develop descriptive and predictive tools using RPM that augment detection of clinical deterioration in pediatric patients as measured by admission, adverse cardiac events and patient reported outcomes within 6-months post intervention.
Study Duration: Patients will be recruited over a 2-year period.
- Conditions
- Heart Failure
- Being tested
- Remote Physiologic Monitoring (RPM)
- Keywords
- remote physiologic monitoring, heart failure, at-risk, telemonitoring technology, pediatric
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote Physiologic Monitoring (RPM)Device
The intervention consists of a remote physiologic monitoring (RPM) program which makes use of a wearable Skiin chest band and ECG device, a blood pressure monitor, a pulse oximeter, and a weight scale; the RPM program will occur for 12 weeks Participants will wear the Skiin device continuously for the first 48-hours and then for a 12-hour span each day following that. Participants will measure their blood pressure, oxygen saturation, and weight once a day for the full 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy | This study will enroll 100 paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy (with systolic or diastolic dysfunction), subjects with congenital heart disease with biventricular or univentricular physiology plus systemic ventricular dysfunction from 4 tertiary heart failure care centres.
Patients will participate in a remote physiologic monitoring program using bluetooth enabled devices for 12 weeks. Devices as part of the study intervention include: Skiin chest band and ECG device; blood pressure monitor; pulse oximeter; weight scale. Receives: Device: Remote Physiologic Monitoring (RPM) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of Remote Physiologic Monitoring (RPM) Program- Recruitment
Feasibility will be assessed by recruitment rates (the number of participants recruited
Measured: 2 years
Feasibility of Remote Physiologic Monitoring (RPM) Program- Retention
Feasibility will be assessed by retention rate (the number of participants who complete measures at baseline and at follow up post intervention)
Measured: 2 years
Feasibility of Remote Physiologic Monitoring (RPM) Program- Access
Feasibility will be assessed by the percentage of people with access to Wi-Fi and smart device
Measured: 2 years
Acceptability of Remote Physiologic Monitoring (RPM) Program
Acceptability will be assessed by compliance defined as >80% of the physiologic monitoring requested has been captured twice daily for a period of 12 weeks; completion of the Medtech 20 questionnaire will also inform on acceptability.
Measured: 2 years
Secondary outcomes (1)
Composite End-Point Assessing Remote Physiologic Monitoring (RPM) Program
For the secondary outcome we will use a composite end-point. Given the low prevalence and rarity of events such as death or transplant from chronic heart failure in paediatrics, there is limited potential for large outcome trials. As a result, we will use a composite end-point designed for the PANORAMA-HF study and based on Packer's composite score which has been extensively used in adult heart failure studies.
Patients will be ranked within 5 categories from worst to best based on heart failure events such as death, transplant listing, need for mechanical circulatory supports, as well as progression of heart failure symptoms by NYHA or Ross Class and patient reported outcomes as assessed by the PedsQL and PGIS. Patients who experience a clinical event during follow up will be classified into category 1 and 2. Patients without a clinical event during follow up will be divided into 3, 4 and 5 based on change from baseline symptoms and functional capacity.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2025
- Study start24 Feb 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Sponsor
- Investigators
- Jennifer L Conway, MD, MSc, Principal investigator, University of Alberta/Stollery Children's HospitalAamir Jeewa, MD, Principal investigator, University of Toronto; The Hospital for Sick Children
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06969560
- Sponsor's protocol ID
- Pro00126084
- Acronym
- WeRoaM:
- Status last verified
- May 2026
- First submitted
- 22 Apr 2025
- Last updated
- 11 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: To protect participant privacy and confidentiality, no IPD will be shared. Only group trends will be reported.
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- There's No Place Like Home…Feasibility of Remote Physiological Monitoring in Childhood Heart Failure
- ClinicalTrials.gov ID
- NCT06969560
- Acronym / sponsor ID
- WeRoaM: / Pro00126084
- Conditions
- Heart Failure
- Keywords
- remote physiologic monitoring, heart failure, at-risk, telemonitoring technology, pediatric
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- 24 Feb 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 14 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Remote physiologic monitoring (RPM) of heart failure (HF) patients with a virtual platform is well established in adult care. However, this technology remains untested in pediatrics and care continues to rely on a hospital-based model which presents challenges in providing equitable access to care for those with lower socio-economic status or living remotely. Telemonitoring technology tailored for children with machine-based algorithms to predict deterioration is needed to facilitate the equitable provision of safe, home-based care, especially in vulnerable populations.
This study will enroll 100 pediatric outpatients with or at risk of deteriorating HF from 4 tertiary pediatric heart failure care centres in Canada. We will use a wearable Bluetooth enabled textile (Skiin device), developed by Myant Inc (Toronto, ON), that can monitor heart rate, heart rhythm, respiratory rate and activity, together with additional home-based monitoring of blood pressure (BP), oxygen saturations and weight. The smart textile will be paired to an RPM platform, SphygmoTM (mmHG Inc).
The goal of this project is to assess the feasibility and acceptability of RPM in pediatrics and validate a RPM-based risk prediction model for pediatric HF patients.
Detailed description
Remote physiologic monitoring (RPM) refers to utilizing non-invasive medical devices to obtain physiologic data, such as pulse oximetry, blood pressure, weight, and electrocardiography at home. Recent advances in RPM have facilitated improved home-based care, reduced hospitalizations, and improved quality of life in adult heart failure populations. Additionally, the integration of multiple physiologic variables acquired through remote physiologic monitoring into machine learning algorithms has been shown to predict hospitalization for heart failure. Previous paediatric studies have demonstrated the utility of incorporating multiple physiologic variables into risk prediction algorithms for cardiac events. This is particularly important in heart failure cohorts where limits of acceptability are often nuanced and patient specific. The use of multiple physiologic parameters creates a more comprehensive insight into the complex pathophysiologic changes in heart failure.
However, the use of RPM devices in children remains limited due to a lack of validated devices and uncertainty about the acceptability and uptake of such interventions. This is partly due to challenges developing devices that can be easily applied, and digital platforms suited to the wider range and variability in body sizes and physiologic parameters. Thus, care of children with heart failure continues to rely on hospital-based models, where tertiary heart failure centers serve large geographically and socio-economically diverse populations. A validated paediatric virtual home monitoring system using RPM to predict clinical deterioration could safely facilitate earlier discharge, reduce the need for outpatient hospital visits, and potentially improve outcomes while minimizing family social disruption and school absence.
The overarching goal of this project is to assess the feasibility of RPM in paediatrics and validate a RPM based risk prediction model for paediatric patients with or at-risk of heart failure, with a view to facilitating safe home-based care across geographically and socially diverse urban, rural, and remote communities. To achieve this goal, this study proposes to utilize a wearable Bluetooth enabled textile (Skiin Device) that can monitor heart rate and rhythm, respiratory rate and activity, together with additional home-based monitoring of blood pressure, oxygen saturations and weight. The textile, developed by Myant (Toronto, ON) has completed pilot testing at SickKids to assess its validity in an outpatient setting (NCT04305340). The Skiin textile will be paired to its software solution, the Myant Health Platform (MHP), which comprises the Skiin Connected Life App (phone application), the Myant Back End (cloud storage of data) and the Myant Virtual Clinical Portal (internet browser visualization of data collected). The Skiin Connected Life App will be used for collection of ECG, heart rate, body temperature, and physical activity throughout the day, and can generate the following average metric for each night when the device is used: resting heart rate, respiratory rate, resting heart rate variability, sleep duration, body temperature.
The MHP will be paired with another RPM platform, SphygmoTM (mmHG Inc). The Sphygmo™ platform consists of a smartphone App (Android, iOS), which can be linked with Bluetooth-compatible devices for automated uploading of measurements to a clinician portal. This platform, originally developed for adults, has the ability to connect with blood pressure, heart rate, weight, and oxygen saturation devices. This platform will be used for collection of additional physiologic data as above and is currently under study at Stollery Children's Hospital. The two systems will have a single-sign on feature allowing their integrated use by the patient, their families, and the research team. We will leverage descriptive and predictive analytics to augment clinician monitoring by defining trajectories and longitudinally predicting risk of key adverse outcomes.
Study Objectives Primary Objectives
- To investigate the feasibility of a remote physiological monitor using a textile smart garment (Skiin devices) using the Skiin Connected Life App along with additional standard home monitoring tools (BP monitor, weigh scales) that are paired with a Bluetooth enabled app (SphygmoTM)
- To test the acceptability of a remote physiological monitor using a textile smart garment (Skiin devices) along with the acceptability of a Bluetooth enabled app (SphygmoTM)
Secondary Objectives
- To leverage analytical methods to develop descriptive and predictive tools using RPM that augment detection of clinical deterioration in pediatric patients as measured by admission, adverse cardiac events and patient reported outcomes within 6-months post intervention.
Study Duration: Patients will be recruited over a 2-year period.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy | – | Device: Remote Physiologic Monitoring (RPM)This study will enroll 100 paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy (with systolic or diastolic dysfunction), subjects with congenital heart disease with biventricular or univentricular physiology plus systemic ventricular dysfunction from 4 tertiary heart failure care centres. Patients will participate in a remote physiologic monitoring program using bluetooth enabled devices for 12 weeks. Devices as part of the study intervention include: Skiin chest band and ECG device; blood pressure monitor; pulse oximeter; weight scale. |
Who may qualify
- Ages
- 8 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- This study will enroll 100 paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy (with systolic or diastolic dysfunction), subjects with congenital heart disease with biventricular or univentricular physiology plus systemic ventricular dysfunction from 4 tertiary heart failure care centres.
Key inclusion criteria (4 listed)
- Patients from 8-18 years of age who are outpatients at time of study enrollment.
- Patients with a chest size of at least 69.85 cm in perimeter/circumference (as measured under the pectoral muscles)
- Patients at-risk for heart failure and with American Heart Association (AHA) Stage B-D Heart Failure will be included in this study irrespective of heart failure medication use.
- HF etiologies include: congenital cardiac malformation with systemic ventricular systolic dysfunction, idiopathic cardiomyopathy, familial/inherited and/or genetic cardiomyopathy, history of myocarditis with persistent ventricular dysfunction, neuromuscular disorder, inborn error of metabolism, mitochondrial disorder, acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional), ischemic (e.g., Kawasaki disease and post-operative HF), and left ventricular non-compaction, restrictive cardiomyopathy and HCM with systolic or diastolic dysfunction.
Key exclusion criteria (6 listed)
- Patients within 3 months of a surgery.
- Patients supported by ventricular assist device at study onset.
- Inability to use technology due to physical or cognitive impairment in the patient or caregiver.
- Non-English speaking.
- Patients who have an implantable cardiac defibrillator or pacemaker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote Physiologic Monitoring (RPM)The intervention consists of a remote physiologic monitoring (RPM) program which makes use of a wearable Skiin chest band and ECG device, a blood pressure monitor, a pulse oximeter, and a weight scale; the RPM program will occur for 12 weeks Participants will wear the Skiin device continuously for the first 48-hours and then for a 12-hour span each day following that. Participants will measure their blood pressure, oxygen saturation, and weight once a day for the full 12 weeks. | Device | paediatric outpatients (8 to 18 years old) with diagnosis of cardiomyopathy |
Primary outcome
Feasibility of Remote Physiologic Monitoring (RPM) Program- Recruitment
Time frame: 2 years
Feasibility will be assessed by recruitment rates (the number of participants recruited
Feasibility of Remote Physiologic Monitoring (RPM) Program- Retention
Time frame: 2 years
Feasibility will be assessed by retention rate (the number of participants who complete measures at baseline and at follow up post intervention)
Feasibility of Remote Physiologic Monitoring (RPM) Program- Access
Time frame: 2 years
Feasibility will be assessed by the percentage of people with access to Wi-Fi and smart device
Acceptability of Remote Physiologic Monitoring (RPM) Program
Time frame: 2 years
Acceptability will be assessed by compliance defined as >80% of the physiologic monitoring requested has been captured twice daily for a period of 12 weeks; completion of the Medtech 20 questionnaire will also inform on acceptability.
1 secondary outcome
Composite End-Point Assessing Remote Physiologic Monitoring (RPM) Program
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2026.
- Individual participant dataSharing planned: No. To protect participant privacy and confidentiality, no IPD will be shared. Only group trends will be reported.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jennifer L Conway, MD, MSc principal investigator
University of Alberta/Stollery Children's Hospital
Aamir Jeewa, MD principal investigator
University of Toronto; The Hospital for Sick Children
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure, run by University of Alberta at 4 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jennifer L Conway, MD, MSc (780-407-4848, jennifer.conway2@ahs.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of Remote Physiologic Monitoring (RPM) Program- Recruitment (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.